Quarterly guidance

Q1 FY2027 Revenue
$130 million to $132 million

Annual guidance

Total Revenue
$550 million to $560 million
AI Drug Discovery Revenue
$100 million
Gross Margin
52.5% to 53%
Adjusted EBITDA
Positive for the full year
Capital Expenditures
Approximately $75 million

Outlook

AI Drug Discovery
Expected to be one of the fastest-growing product groups in fiscal 2027 with accelerating order momentum.
Capacity Expansion
Investing to increase DNA writer capacity to over 50 million pieces daily and expanding characterization labs.
Nucleic Acid Therapeutics
Viewed as a medium- to long-term opportunity that does not require material contribution to meet growth targets.
MRD Express
Expected to drive growth in fiscal 2027 and beyond as commercial adoption increases.
Margins
Expect gross margin expansion to continue, though at a slower pace due to depreciation costs from new capacity.